Major Depressive Disorder
Stories
-
Janssen posts results of Phase 3 seltorexant trial in major depressive disorder with insomnia
The study enrolled 757 participants and began on September 15, 2020, with primary completion on October 3, 2023. It compared seltorexant 20 mg to quetiapine XR as adjunctive therapy to antidepressants in adults and elderly patients with major depressive disorder with insomnia symptoms who had responded inadequately to antidepressant therapy.